JP Morgan Maintains Overweight on Insmed, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Insmed (NASDAQ:INSM) and raises the price target from $72 to $74.
October 03, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye has reaffirmed an Overweight rating on Insmed and increased the price target from $72 to $74, indicating a positive outlook.
The increase in price target from $72 to $74 by a reputable analyst at JP Morgan suggests a positive outlook for Insmed, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100